Efficiency of three surgical procedures in eliminating high­risk human papillomavirus infection in women with precancerous cervical lesions

Purpose of investigation: To establish the efficiency of laser vaporization (LV), large loop excision of the transformation zone (LLETZ) and cold knife conization, done for precancerous cervical lesions, in eliminating high-risk human papillomavirus (HPV) infection. Additionally, we determined whether the same HPV genotype persisted after surgery.

Methods: A total of 214 women were tested for HPV infection by the Hybrid Capture II (HCII) test prior to surgery. HPV-positive women were followed by HCII test ten months after surgery. In persistently HPV-positive women, HPV genotypes were determined by PCR - PGMY09/PGMY11.

Results: The HCII test showed elimination of HPV infection after LV, LLETZ and cold knife conization in 67.6%, 86.3%, and 100% (p < 0.05) of women, respectively. In seven (38.9%) women a different HPV genotype was found to be present after surgery, the corrected efficiency thus being 79.4%, 92.7% and 100% (p = NS), respectively.

Conclusions: The three analyzed surgical procedures are effective in eliminating high-risk HPV infection. HPV testing is useful at follow-up, since it can identify a small proportion of women requiring close surveillance and potential treatment.

Human papillomavirus; Precancerous cervical lesions; Surgical treatment; Follow-up

[1] Ponten J., Adami H.O., Bergstrom R., Dillner J., Friberg L.G., Gustafsson L. et al.: "Strategies for global control of cervical cancer". Int. J. Cancer, 1995, 60, 1, 1.

[2] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al.: "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide". J. Pathol., 1999, 189, 1, 12.

[3] Bosch F.X., Munoz N.:'The viral etiology of cervical cancer". Virus. Res., 2002, 89, 2, 183.

[4] Lytwyn A., Sellors J.W., Mahony J.B., Daya D., Chapman W., Ellis N. et al.: "Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group". CMAJ, 2000, 163, 6, 701.

[5] Kim J.J., Wright TC., Goldie SJ.: "Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance". JAMA, 2002, 287, 18, 2382.

[6] Wright T.C. Jr., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J.: "2001 Consensus Guidelines for the management of women with cervical cytological abnormalities". JAMA, 2002, 287, 16, 2120.

[7] Wright T.C. Jr., Cox J.T., Massad L.S., Carlson J., Twiggs L.B., Wilkinson E.J.: "2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia". Am. J. Obstet. Gynecol., 2003, 189, 1, 295.

[8] Wright TC. Jr., Schiffman M.: "Adding a test for human papillornavirus DNA to cervical-cancer screening". N. Engl. J. Med., 2003, 348, 6, 489.

[9] Petry K.U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B. et al.: "Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients". Br. J. Cancer., 2003, 88, 10, 1570.

[10] Wright TC. Jr., Sch市man M., Solomon D., Cox J.T., Garcia F., Goldie S. et al.: "Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening". Obstet. Gynecol., 2004, 103, 2, 304.

[11] Agnantis N.J., Sotiriadis A., Paraskevaidis E.: "The current status of HPV DNA testing". Eur. J. Gynaecol. Oneal., 2003, 24, 5, 351.

[12] Bodner K.,B odner-Adler B.,W ierrani F.,K imberger 0.,D enk C., Grunberger W.: "Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis". Anticancer. Res., 2002, 22, 6B, 3733.

[13] Chao A., Lin C.T., Hsueh S., Chou H.H., Chang TC., Chen M.Y et al.: "Usefulness of human papillomavirus testing in the followup of patients with high-grade cervical intraepithelial neoplasia after conization". Am. J. Obstet. Gynecol., 2004, 190, 4, 1046.

[14] Elfgren K., Jacobs M., Walboomers J.M., Meijer C.J., Dillner J "Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia". Obstet. Gynecol., 2002, JOO, 5 Pt 1. 965.

[15] Costa S., De Simone P., Venturoli S., Cricca M., Zerbini M.L., Musiani M. et al.: "F actors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization". Gynecol. Oncol., 2003, 90, 2, 358.

[16J Poljak M., Seme K.: "Rapid detection and typing of human papillomaviruses by consensus polymerase chain reaction and enzymelinked immunosorbent assay". J. Viral. Methods., 1996, 56, 2, 231.

[17] Poljak M., Marin J.J., Seme K., Vince A.: "Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail". J. Clin. Virol., 2002, 25 (suppl. 3), S89.

[18] Munoz N.,B osch F.X.,d e Sanjose S.,H errero R.,C astellsague X., Shah K.V. et al.: "Epidemiologic classification of human papillomavirus types associated with cervical cancer". N. Engl. J. Med., 2003, 348, 6, 518.

[19] Kucera E.. Sliutz G.. Czerwenka K., Breitenecker G., Leodolter S., Reinthaller A.: "Is high-risk human papillornavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone?" Eur. J. Obstet. Gynecol. Reprod. Biol., 2001, 100, 1, 72.

[20] Houfflin Debarge V., Collinet P., Vinatier D., Ego A., Dewilde A., Boman F. et al.: "Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squarnous intraepithelial lesions". Gynecol. Oneal., 2003, 90, 3, 587.

[21] Ho G.Y., Bierman R., Beardsley L., Chang CJ., Burk R.D "Natural history of cervicovaginal pap仆lornavirus infection in young women". N. Engl. J. Med., 1998, 338, 7, 423.

[22] Kjaer S.K., van den Brule A.J., Bock J.E., Poll P.A., Engholm G., Sherman M.E. et al.: "Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types?". Cancer. Epidemiol Biomarkers. Prev., 1997, 6, 10, 799.

[23] Franceschi S.: "The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer". Recent. Results. Cancer. Res., 2005, 166, 277.

[24] Munoz N.: "Human pap让Jomavirus and cancer: the epidemiological evidence". J. Clin. Viral., 2000, 19, 1, 1.

[25] Smrkolj S., Rakar S., Mozina A., Erzen M.: "Evaluation of causes of increased incidence of cervical cancer in Slovenia". Eur. J Obstet. Gynecol. Reprod. Biol., 2004, 117, 2, 213.

[26] Vrtacnik-Bokal E., Rakar S., Mozina A., Poljak M.: "Human papillomavirus infection in relation to mild dyskaryosis in conventional cervical cytology". Eur. J Gynaecol. Oneal., 2005, 26, 1, 39.

[27] Vrtacnik-Bokal E., Rakar S., Jancar N., Mozina A., Poljak M.: "Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions". Eur. J Gynaecol. Oncol., 2005, 26, 4, 427.